We are a tissue regeneration company dedicated to using innovative cell technologies, advancing patient wound care and healing processes.
Elanix develops and markets progenitor cell-based products to help regenerate tissue and promote healing in the treatment of burns, gynecological and dermatological conditions. The Company is headquartered in Nyon, Canton Vaud, Switzerland, with offices in Wiesbaden, Germany, and listed on the Frankfurt stock exchange under the symbol ELN.
Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix enhances the activity of progenitor cells with proprietary cytokine formulations to create unique cell therapy products and procedures.
MARKETED PRODUCTS & PIPELINE
Elanix owns two cosmetic creams, GYNrepair® and RepAir-A N, marketed in Switzerland since 2011 in gynecology and dermatology.
Elanix is developing a bioresorbable & bioactive skin dressing derived from progenitor skin fibroblasts to accelerate regeneration and improve quality of skin following acute burns.
Financial information and stock performance data can be found in the Investor Relations sections.